BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
One other thing I wanted to highlight for this trial, and maybe we'll come back to that as well, is the patient population here. So we looked at patients that were T2 to T4, N0 and N1. So there were some node positive patients here. And of course, in the comparator arm, patients were randomized to get just GEMSYS and radical cystectomy, didn't get any adjuvant treatment.
0
💬
0
Comments
Log in to comment.
There are no comments yet.